CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

The company’s Convidecia has received emergency-use authorization from the World Health Organization, becoming the third Chinese vaccine to get that nod Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited benefits for the company as the pandemic fades and other products are widely available By Jony Ho As the Covid-19 pandemic recedes and countries start to reopen, the World Health Organization (WHO) has just granted an emergency-use license to yet another Chinese vaccine. But…

Read More »

AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM has filed for an IPO in Hong Kong, following unsuccessful previous bids in Hong Kong and on Shenzhen’s ChiNext board The company has three Covid vaccines under development, including an mRNA vaccine expected to hit the market in the fourth quarter By Fai Pui If at first you don’t succeed, try, try again. And again. And again. That’s the mantra…

Read More »

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Company licensed to sell BioNTech’s mRNA vaccine in China reported its revenue rose 28.8% last year, with the Comirnaty vaccine bringing in over $157 million Key takeaways: Fosun Pharma’s revenue and profit both rose around 30% last year as Covid-19 vaccines and stake sales in its subsidiaries contributed to its top and bottom lines The company’s gross margin fell sharply as some of its drugs were added to government procurement programs that promise higher sales but at heavy discounts By Molly Wen Vaccines have been the most potent weapon in…

Read More »

Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field

Global agreement for oral anti-viral comes just months after company signed separate similar tie-up for a Covid mRNA vaccine also in development Key Takeaways Everest has signed a global licensing deal for an anti-viral Covid treatment being developed by Singapore’s Experimental Drug Development Centre Similar oral anti-viral treatments have been developed by Pfizer and Merck, and are growing in popularity due to their ease of use By Richard Barbarossa Why settle for a single drug to treat Covid-19 when you can hedge your bets with two? That appears to be…

Read More »